Molecular Biomarker-Based Personalized Medicine Opportunities and Challenges in Cancer Treatment Report and National Cancer Policy Roadmap Multi-Stakeholder Workshop, where relevant stakeholders came together to initiate personalized oncology national action plan studies for our country by following the global developments in the field of cancer, from the perspective of Health Authority, Reimbursement Agency and Clinician, was held on February 15, 2022 at JW Marriott Hotel Ankara, hosted by Prof. Dr. Şuayib Yalçın, Secretary General of the Turkish Association for Cancer Research and Control, with the contributions of WHO European Office and Ankara University, and with the coordination of Rx Corporate Communications.

The prominent opinion leaders of our country, Prof. Dr. Şuayib Yalçın, Prof. Dr. Toker Ergüder, Prof. Dr. Emel Cabi Ünal, Prof. Dr. Nalan Akyürek, Prof. Dr. Mehmet Ali Nahit Şendur, Assoc. Prof. Dr. Atıl Bişgin and (MSc) Pharm. Burcum Uzunoğlu   were present at the Multi-Stakeholder Workshop, which was attended by the Ministry of Health, General Directorate of Public Health Cancer Department, Turkish Medicines and Medical Devices Agency, Department of Economic Assessments and Medicine Supply Management, TÜSEB (Health Institutes of Turkey), TÜBİTAK (The Scientific and Technological Research Council of Turkey), Social Security Institution General Health Insurance General Directorate, Medicines Department and Foreign Health Services Department.

Deputy Assoc. Prof. Dr. Ali Muhittin Taşdoğan, Gaziantep Deputy and Member of TBMM (Grand National Assembly of Turkey) Health, Family, Labor and Social Affairs Commission, participated in the Multi-Stakeholder Workshop, emphasized the need for treatment guides, legal regulations and legislation for providing targeted personalized cancer treatments to patients in a timely manner in his assessment of the need for National Policy on Molecular Biomarker-Based Personalized Oncology, and said that utilizing health technology assessment methods would provide contribution to the processes of access to treatment.

The National Policy and Roadmap, which is needed for Personalized Cancer Treatments, was evaluated from the perspective of Health Authority, Reimbursement Agency, and Clinician, taking into account various aspects, and Multi-Stakeholder Workshop Report has been drawn up, which is planned to provide guidance for policy makers and decision-makers.

Challenges & Opportunities in Molecular Biomarker Based Personalized Precision Medicine in the Treatment of Cancer Workshop was held at JW Marriott Hotel Ankara on 16 June 2021 hosted by Prof. Dr. Şuayib Yalçın, President of Turkish Association for Cancer Research and Control.

In the Workshop, which was held in two plenary sessions; Molecular Biomarker Based Targeted Personalized Medicine Definition and Estimated impact in the Turkish healthcare setting, associated Problems & possible Opportunities are evaluated and Solution Proposals were discussed.

Prof. Dr. Şuayib Yalçın, Prof. Dr. Faysal Dane, Prof. Dr. Emel Cabi Ünal, Prof. Dr. Nalan Akyürek, Prof. Dr. Nuriye Özdemir, Prof. Dr. Mehmet Ali Nahit Şendur, Prof. Dr. Toker Ergüder, Assoc. Prof. Dr. Hilmi Kodaz, Assoc. Prof. Dr. Atıl Bişgin, Spec. Dr. Hakan Taban, (MSc) Pharm. Burcum Uzunoğlu   has attended and contributed to the Workshop.

Member of the TBMM Health, Family, Labor and Social Affairs Commission, Gaziantep Deputy Assoc. Prof. Dr. Ali Muhittin Taşdoğan has actively participated in the Workshop, shared the policy activities conducted in the Parliament regarding the urgent need for National Policy on Personalized Medicine and Personalized Oncology, and examined the opinions of the Key Opinion Leaders.

The required national policy and legislative changes in Personalized Cancer Treatments were defined scientifically from a clinician's point of view, and The Workshop Report: Challenges & Opportunities In Molecular Biomarker-Based Personalized Precision Medicine In The Treatment of Cancer has been generated and presented to policy makers and decision makers.